Jim McMenamin

10.7k total citations · 2 hit papers
109 papers, 4.0k citations indexed

About

Jim McMenamin is a scholar working on Epidemiology, Infectious Diseases and Modeling and Simulation. According to data from OpenAlex, Jim McMenamin has authored 109 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Epidemiology, 29 papers in Infectious Diseases and 15 papers in Modeling and Simulation. Recurrent topics in Jim McMenamin's work include Influenza Virus Research Studies (53 papers), Respiratory viral infections research (46 papers) and COVID-19 epidemiological studies (15 papers). Jim McMenamin is often cited by papers focused on Influenza Virus Research Studies (53 papers), Respiratory viral infections research (46 papers) and COVID-19 epidemiological studies (15 papers). Jim McMenamin collaborates with scholars based in United Kingdom, France and Sweden. Jim McMenamin's co-authors include Chris Robertson, Nick Andrews, Richard Pebody, Simon Cottrell, Joanna Ellis, Aziz Sheikh, Maria Zambon, Colin R Simpson, Jamie Lopez Bernal and Julia Stowe and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jim McMenamin

108 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

2021 744 citations Jamie Lopez Bernal, Nick Andrews et al. BMJ profile →
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design

2022 154 citations Aziz Sheikh, Jim McMenamin et al. profile →

Peers

Countries citing papers authored by Jim McMenamin

Since Specialization

Citations

This map shows the geographic impact of Jim McMenamin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim McMenamin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim McMenamin more than expected).

Fields of papers citing papers by Jim McMenamin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim McMenamin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim McMenamin. The network helps show where Jim McMenamin may publish in the future.

Co-authorship network of co-authors of Jim McMenamin

This figure shows the co-authorship network connecting the top 25 collaborators of Jim McMenamin. A scholar is included among the top collaborators of Jim McMenamin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim McMenamin. Jim McMenamin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An intercountry comparison of the impact of the paediatric live attenuated influenza vaccine (LAIV) programme across the UK and the Republic of Ireland (ROI), 2010 to 2017 2023 ·Influenza and Other Respiratory Viruses ·Mary Sinnathamby, Fiona Warburton, Arlene Reynolds, Simon Cottrell, Mark G. O’Doherty, Lisa Domegan, Joan O’Donnell, Jillian Johnston, Ivelina Yonova, (unknown), Nicki L. Boddington, Nick Andrews, Joanna Ellis, Simon de Lusignan, Jim McMenamin, Richard Pebody	4
2	Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned 2022 ·Eurosurveillance ·Jayshree Bagaria, Tessa Jansen, Diogo Marques, Mariëtte Hooiveld, Jim McMenamin, Simon de Lusignan, (unknown), Adam Meijer, (unknown), Mia Brytting, Clara Mazagatos, (unknown), Sylvie van der Werf, Frederika Dijkstra, Raquel Guiomar, Theresa Enkirch, Marta Valenciano, (unknown)	19
3	SARS-CoV-2 tests, confirmed infections and COVID-19-related hospital admissions in children and young people: birth cohort study 2022 ·BMJ Paediatrics Open ·Pia Hardelid, Graziella Favarato, Linda Wijlaars, Lynda Fenton, Jim McMenamin, Tom Clemens, Chris Dibben, Ai Milojevic, Alison Macfarlane, Jonathon Taylor, Steve Cunningham, Rachael Wood	4
4	Epidemiological analysis of Legionnaires' disease in Scotland: a genomic study 2022 ·The Lancet Microbe ·(unknown), Bryan A. Wee, Melissa Llano, Joana Alves, Ross Cameron, Jim McMenamin, Andrew Smith, Diane Lindsay, J. Ross Fitzgerald	8
5	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study 2021 ·BMC Medicine ·Paul McKeigue, David McAllister, David Caldwell, Ciara Gribben, Jen Bishop, Stuart J. McGurnaghan, Matthew J. Armstrong, (unknown), (unknown), Sharon Hutchinson, Chris Robertson, Nazir Lone, Jim McMenamin, David Goldberg, Helen M. Colhoun	14
6	Temporal trends and forecasting of COVID-19 hospitalisations and deaths in Scotland using a national real-time patient-level data platform: a statistical modelling study 2021 ·The Lancet Digital Health ·Colin R Simpson, Chris Robertson, Eleftheria Vasileiou, Emily Moore, Colin McCowan, Utkarsh Agrawal, Helen R. Stagg, Annemarie B Docherty, Rachel Mulholland, Josie Murray, Lewis Ritchie, Jim McMenamin, Aziz Sheikh	15
7	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study breakdown → 2021 ·BMJ ·Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, Chris Robertson, Julia Stowe, Elise Tessier, Ruth Simmons, Simon Cottrell, Richard J. Roberts, Mark G. O’Doherty, Kevin Brown, Claire Cameron, Diane Stockton, Jim McMenamin, Mary Ramsay	744
8	Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study 2020 ·Health Technology Assessment ·Colin R Simpson, Nazir Lone, Kimberley Kavanagh, (unknown), Chris Robertson, Jim McMenamin, (unknown), Eleftheria Vasileiou, Christopher Butler, Lewis Ritchie, Rory Gunson, Jürgen Schwarze, Aziz Sheikh	7
9	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 ·PLoS Medicine ·Paul McKeigue, Amanda Weir, Jen Bishop, Stuart J. McGurnaghan, Sharon Kennedy, David McAllister, Chris Robertson, Rachael Wood, Nazir Lone, Janet Murray, Thomas M. Caparrotta, Alison Smith‐Palmer, David Goldberg, Jim McMenamin, Colin N. Ramsay, Sharon Hutchinson, Helen M. Colhoun, (unknown)	44
10	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study 2020 ·BMJ ·Anoop Shah, Rachael Wood, Ciara Gribben, David Caldwell, Jennifer L. Bishop, Amanda Weir, Sharon Kennedy, Martin Reid, Alison Smith‐Palmer, David Goldberg, Jim McMenamin, Colin Fischbacher, Chris Robertson, Sharon Hutchinson, Paul McKeigue, Helen M. Colhoun, David McAllister	219
11	Modelling the population effectiveness of the national seasonal influenza vaccination programme in Scotland: The impact of targeting all individuals aged 65 years and over 2018 ·Influenza and Other Respiratory Viruses ·Stephen L. Corson, Chris Robertson, Arlene Reynolds, Jim McMenamin	4
12	Effectiveness of influenza vaccination for preventing influenza-related complications in people with asthma: a systematic review protocol 2016 ·BMJ Open ·Eleftheria Vasileiou, Aziz Sheikh, Christopher Butler, Beatrix von Wissmann, Jim McMenamin, Lewis Ritchie, (unknown), Colin R Simpson	3
13	Seasonal Influenza Vaccine Effectiveness in the community (SIVE): protocol for a cohort study exploiting a unique national linked data set 2012 ·BMJ Open ·Nazir Lone, Colin R Simpson, Kimberley Kavanagh, Chris Robertson, Jim McMenamin, Lewis Ritchie, Aziz Sheikh	16
14	Knowledge of tuberculosis transmission among recently infected patients in Glasgow 2008 ·Public Health ·(unknown), Jim McMenamin, (unknown), S. Faisal Ahmed, Marvin Reid	3
15	Do HIV Disease Progression and HAART Response Vary among Injecting Drug Users in Europe? 2005 ·European Journal of Epidemiology ·Liselotte van Asten, Robert Zangerle, Ildefonso Hernández‐Aguado, Faroudy Boufassa, Barbara Broers, R.P. Brettle, Roy Robertson, Jim McMenamin, Roel A. Coutinho, Maria Prins	9
16	Hospital transmission of hepatitis B virus in the absence of exposure prone procedures 2005 ·Epidemiology and Infection ·(unknown), (unknown), (unknown), A. Duncan Walker, (unknown), (unknown), (unknown), Jim McMenamin, (unknown), Daniel R. Morrison, Julie Armstrong, David S. Goldberg	3
17	The United Kingdom's hepatitis B immunisation strategy--where now? 1998 ·PubMed ·(unknown), Jim McMenamin	16
18	The recent impact of antiretroviral combination therapy on CD4 counts, AIDS and death in HIV-infected persons: routine HIV surveillance in Scotland 1998 ·International Journal of STD & AIDS ·Gwen M. Allardice, Jim McMenamin, Tamiza Parpia, (unknown), Charles McSharry, (unknown)	17
19	The Molecular Epidemiology of Human Immunodeficiency Virus Type 1 in Six Cities in Britain and Ireland 1997 ·Virology ·Andrew Brown, (unknown), Christopher M. Wade, Selma Rebus, A. N. Phillips, R P Brettle, A J France, Clifford Leen, Jim McMenamin, A McMillan, (unknown), F Mulcahy, J R Robertson, (unknown), G R Scott, (unknown), J F Peutherer	31
20	Reducing risks in blood transfusion: process and outcome 1996 ·Transfusion Medicine ·D. B. L. McClelland, Jim McMenamin, (unknown), J. A. J. Barbara	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact